Nisa Investment Advisors
CERE

Nisa Investment Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Nisa Investment Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-717
Closed -$29.3K – 3083
2024
Q2 		$29.3K Buy
717
+60
+9% +$2.5K ﹤0.01% 1815
2024
Q1 		$27.8K Buy
657
+57
+10% +$2.39K ﹤0.01% 1793
2023
Q4 		$25.4K Buy
600
+20
+3% +$575 ﹤0.01% 1811
2023
Q3 		$12.7K Sell
580
-1,120
-66% -$28K ﹤0.01% 2127
2023
Q2 		$54K Buy
1,700
+280
+20% +$8.59K ﹤0.01% 1729
2023
Q1 		$35K Hold
1,420
– – ﹤0.01% 1821
2022
Q4 		$45K Hold
1,420
– – ﹤0.01% 1816
2022
Q3 		$40K Buy
1,420
+40
+3% +$1.19K ﹤0.01% 1833
2022
Q2 		$36K Buy
1,380
+440
+47% +$12.5K ﹤0.01% 1857
2022
Q1 		$33K Sell
940
-1,256
-57% -$36.7K ﹤0.01% 1947
2021
Q4 		$57K Buy
+2,196
New +$77.5K ﹤0.01% 1699

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Nisa Investment Advisors's CERE Position: Q3 2024 in Review

Nisa Investment Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 717 shares — an estimated $29.3K sold.

Nisa Investment Advisors first reported a position in CERE in Q4 2021 and held it in 11 quarters. The position peaked at $57K in Q4 2021. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Nisa Investment Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Nisa Investment Advisors sold 717 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $29.3K.
  • Nisa Investment Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 11 quarters.
  • Nisa Investment Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $57K in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Nisa Investment Advisors's 13F filing for Q3 2024, filed 24 Oct 2024.